Symbiosis invests $1.9m in UK sterile biologics facility expansion

Published: 17-Dec-2019

UK-based CMO has expanded its Scottish facility driven by the market growth of ATMPs such as viral vector and other biopharmaceuticals

Sterile manufacturing specialist and CMO Symbiosis Pharmaceutical Services has expanded its sterile biologics manufacturing facility in the UK by 25%.

In the last 12 months Symbiosis has invested over $1.9 million in the expansion of its Stirling site, doubling its current footprint with an additional 8,000 sqft of office space to house the firm’s administrative, management and operational teams while also facilitating the expansion of its existing manufacturing space and its supporting services infrastructure.

The new operational area also provides additional capacity for GMP-compliant manufacturing services for improved supply chain management including additional temperature controlled storage and the company’s first automated labelling and packaging equipment.

Colin MacKay, CEO at Symbiosis said: “This represents another exciting step for Symbiosis which allows the company to continue to leverage its expertise in small scale clinical and commercial sterile manufacturing to drive future growth.”

MacKay explained that the additional space has allowed the company to increase its headcount from 60 to 90 employees.

“The investment in the new facility is driven by the significant organic growth of the company as a result of its continued success in the niche market of sterile manufacturing of advanced therapeutic medicinal products (ATMPs) such as viral vector and other biopharmaceuticals - our customer base has grown by more than 25% in 2019 alone.”

The expanded facility, which was recently completed and is now fully operational, has been part-funded by a successful Innovate UK grant from the UK Government aimed directly at strengthening the UK’s viral vector biopharmaceutical drug development and manufacturing supply chain. The continued investment and demand for services is estimated to increase output by another 25-30% in 2020.

Colin MacKay continued: “The strategic focus of Symbiosis for 2020 is on the continued organic growth of our core sterile GMP manufacturing services in our key target markets in the US and Europe. Expanding the level of viral vector sterile manufacturing is central to that strategy, and we have a number of new and current client project initiatives which are further driving that expansion.”

As well as the growth of its specialist viral vector filling services, Symbiosis services the demand for sterile fill-finish of conventional small molecule drugs in both liquid and lyophilised formulations for clinical trials, and also has experience of supporting fast-track international commercial product registration.

You may also like